NCT01647789View on ClinicalTrials.gov

A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

December 4, 2012

Primary Completion Date

February 3, 2016

Study Completion Date

February 3, 2016

Conditions
Prostatic Neoplasms
Interventions
DRUG

CFG920

Trial Locations (7)

5004

Novartis Investigative Site, Bouge

53792

University of Wisconsin Univ Wisc, Madison

78229

Cancer Therapy & Research Center UT Health Science Center InstituteForDrugDevelopment(2), San Antonio

94143

UCSF Medical Center Dept of Oncology, San Francisco

98105

Seattle Cancer Care Alliance Dept. of SCCA, Seattle

L8V 5C2

Novartis Investigative Site, Hamilton

08035

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY